{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:19:01Z","timestamp":1761513541415,"version":"build-2065373602"},"reference-count":31,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.clbc.2017.04.005","type":"journal-article","created":{"date-parts":[[2017,4,14]],"date-time":"2017-04-14T05:30:41Z","timestamp":1492147841000},"page":"427-432","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Multi-institutional Evaluation of Women at High Risk of Developing Breast Cancer"],"prefix":"10.1016","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6342-6023","authenticated-orcid":false,"given":"David J.","family":"Hermel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie E.","family":"Wood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Chun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiffany","family":"Rounds","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa","family":"Sands","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shira","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Freya R.","family":"Schnabel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2016","series-title":"Cancer Facts & Figures\u00a02016","key":"10.1016\/j.clbc.2017.04.005_bib1"},{"key":"10.1016\/j.clbc.2017.04.005_bib2","unstructured":"Howlader N, Noone AM, Krapcho M, et\u00a0al, eds. SEER Cancer Statistics Review, 1975-2010. Bethesda: National Cancer Institute. November 2012 SEER data submission, posted to the SEER web site, April 2013. Available at: http:\/\/seer.cancer.gov\/csr\/1975_2010\/. Accessed: June 4, 2016."},{"key":"10.1016\/j.clbc.2017.04.005_bib3","first-page":"186","article-title":"Priorities for the primary prevention of breast cancer","volume":"64","author":"Colditz","year":"2014","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clbc.2017.04.005_bib4","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1007\/s00280-016-2959-0","article-title":"The selective estrogen receptor modulators in breast cancer prevention","volume":"77","author":"Li","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.clbc.2017.04.005_bib5","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1093\/jnci\/dji372","article-title":"Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study","volume":"97","author":"Fisher","year":"2005","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clbc.2017.04.005_bib6","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1093\/jnci\/djh319","article-title":"Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene","volume":"96","author":"Martino","year":"2004","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clbc.2017.04.005_bib7","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1200\/JCO.2013.49.3122","article-title":"Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline","volume":"31","author":"Visvanathan","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2017.04.005_bib8","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1056\/NEJM199901143400201","article-title":"Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer","volume":"340","author":"Hartmann","year":"1999","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clbc.2017.04.005_bib9","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1001\/jama.2010.1237","article-title":"Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality","volume":"304","author":"Domchek","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.clbc.2017.04.005_bib10","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1200\/JCO.2004.04.188","article-title":"Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group","volume":"22","author":"Rebbeck","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2017.04.005_bib11","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1056\/NEJM200107193450301","article-title":"Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation","volume":"345","author":"Meijers-Heijboer","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clbc.2017.04.005_bib12","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2005.04.5260","article-title":"ASCO\/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes","volume":"24","author":"Guillem","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2017.04.005_bib13","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s10549-014-3234-x","article-title":"The impact of cancer prevention guideline adherence on overall mortality in a high-risk cohort of women from the New York site of the Breast Cancer Family Registry","volume":"149","author":"Cloud","year":"2015","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clbc.2017.04.005_bib14","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1038\/bjc.2013.807","article-title":"Reproductive risk factors and oestrogen\/progesterone receptor-negative breast cancer in the Breast Cancer Family Registry","volume":"110","author":"Work","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clbc.2017.04.005_bib15","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1053\/j.seminoncol.2009.03.001","article-title":"Breast cancer before age 40 years","volume":"36","author":"Anders","year":"2009","journal-title":"Semin Oncol"},{"key":"10.1016\/j.clbc.2017.04.005_bib16","first-page":"51","article-title":"Health disparities and cancer: racial disparities in cancer mortality in the United States, 2000-2010","volume":"3","author":"O'Keefe","year":"2015","journal-title":"Front Public Health"},{"key":"10.1016\/j.clbc.2017.04.005_bib17","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/sj.bjc.6604830","article-title":"Breast cancer risks in women with a family history of breast or ovarian cancer who have tested negative for a BRCA1 or BRCA2 mutation","volume":"100","author":"Metcalfe","year":"2009","journal-title":"Br J Cancer"},{"issue":"suppl 2","key":"10.1016\/j.clbc.2017.04.005_bib18","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1016\/j.breast.2015.07.013","article-title":"Impact of preventive therapy on the risk of breast cancer among women with benign breast disease","volume":"24","author":"Cuzick","year":"2015","journal-title":"Breast"},{"key":"10.1016\/j.clbc.2017.04.005_bib19","doi-asserted-by":"crossref","first-page":"4505","DOI":"10.1200\/JCO.2010.34.4440","article-title":"Breast cancer risk for noncarriers of family-specific BRCA1 and BRCA2 mutations: findings from the Breast Cancer Family Registry","volume":"29","author":"Kurian","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2017.04.005_bib20","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1093\/jnci\/95.7.526","article-title":"Estimates of the number of US women who could benefit from tamoxifen for breast cancer chemoprevention","volume":"95","author":"Freedman","year":"2003","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clbc.2017.04.005_bib21","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1200\/JCO.2009.27.8077","article-title":"Patient decisions about breast cancer chemoprevention: a systematic review and meta-analysis","volume":"28","author":"Ropka","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2017.04.005_bib22","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1158\/1940-6207.CAPR-11-0380","article-title":"Predicting adherence to tamoxifen for breast\u00a0cancer adjuvant therapy and prevention","volume":"4","author":"Lin","year":"2011","journal-title":"Cancer Prev Res (Phila)"},{"key":"10.1016\/j.clbc.2017.04.005_bib23","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/jnci\/dju354","article-title":"Risk-benefit profiles of women using tamoxifen for chemoprevention","volume":"107","author":"Nichols","year":"2015","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clbc.2017.04.005_bib24","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1037\/hea0000324","article-title":"Affective forecasting and medication decision making in breast-cancer prevention","volume":"35","author":"Hoerger","year":"2016","journal-title":"Health Psychol"},{"key":"10.1016\/j.clbc.2017.04.005_bib25","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1002\/cncr.20205","article-title":"Acceptance of tamoxifen chemoprevention by physicians and women at risk","volume":"100","author":"Tchou","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.clbc.2017.04.005_bib26","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1093\/jnci\/90.18.1371","article-title":"Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study","volume":"90","author":"Fisher","year":"1998","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clbc.2017.04.005_bib27","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMra1503523","article-title":"The role of risk-reducing surgery in hereditary breast and ovarian cancer","volume":"374","author":"Hartmann","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clbc.2017.04.005_bib28","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s12905-014-0150-5","article-title":"Risk-reducing salpingo-oophorectomy: a meta-analysis on impact on ovarian cancer risk and all cause mortality in BRCA 1 and BRCA 2 mutation carriers","volume":"14","author":"Marchetti","year":"2014","journal-title":"BMC Womens Health"},{"key":"10.1016\/j.clbc.2017.04.005_bib29","doi-asserted-by":"crossref","first-page":"djv033","DOI":"10.1093\/jnci\/djv033","article-title":"Breast cancer risk after salpingo-oophorectomy in healthy BRCA1\/2 mutation carriers: revisiting the evidence for risk reduction","volume":"107","author":"Heemskerk-Gerritsen","year":"2015","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clbc.2017.04.005_bib30","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1002\/ijc.23340","article-title":"International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers","volume":"122","author":"Metcalfe","year":"2008","journal-title":"Int J Cancer"},{"key":"10.1016\/j.clbc.2017.04.005_bib31","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s13058-015-0650-8","article-title":"Longer term effects of the Angelina Jolie effect: increased risk-reducing mastectomy rates in BRCA carriers and other high-risk women","volume":"17","author":"Evans","year":"2015","journal-title":"Breast Cancer Res"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820916302646?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820916302646?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:15:52Z","timestamp":1761513352000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820916302646"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["S1526820916302646"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2017.04.005","relation":{},"ISSN":["1526-8209"],"issn-type":[{"type":"print","value":"1526-8209"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multi-institutional Evaluation of Women at High Risk of Developing Breast Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2017.04.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}